Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib and KTN3379 in BRAF Mutant RAIR Thyroid Cancer
NCT02456701Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Jun 2015
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cdx-3379 in thyroid cancer, sponsored by Celldex Therapeutics. Primary endpoint: Number of patients with increased tumoral iodine incorporation warranting 131I treatment. Started Jun 2015; status: completed.
02
Drugs
cdx-3379
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT02456701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456701.